News / Africa

    Africa Urged to Increase Monitoring of Drug Trials

    New drugs must be tested before they can be sold. Ethical testing requires what’s called 'informed consent,' which means the participants must not only agree to take part but also have a real understanding of the procedure. But some of those tests, or clinical trials, have come under criticism. Some pharmaceutical companies have been accused of exploiting the test subjects, who may not understand how the process works.

    A number of international documents set ethical standards for drug trials, including the World Medical Association’s Declaration of Helsinki and the WHO’s Good Clinical Practice Guidelines. They stipulate that medical experiments with human subjects must uphold the highest respect for the rights and welfare of study participants.

    Some drug companies say they do meet ethical standards. For instance, the U.S.-based Pfizer company has its own guidelines. They include allowing independent ethics institutions to validate the process before the trials begin and obtaining informed consent from trial subjects. They also call for limiting risks as much as possible and guaranteeing healthcare for participants who emerge with complications.

    Problems

    But the international guidelines and strong ethical frameworks are not mandatory.

    Critics point to controversies that they say involved wealthy Western drug companies and poorly informed subjects. An official in Cameroon’s Ministry of Health who wished to remain anonymous said researchers testing new drugs in the country have sidestepped both national and international guidelines.

    Health care activists want to be sure all participants understand what's involved in a drug trial
    Health care activists want to be sure all participants understand what's involved in a drug trial

    One case in 2005, an antiviral AIDS medication, made headlines around the world, and other clinical trials have led to abuses as well.

    In that case, ethics violations in Cameroon put an end to clinical trials for tenofovir, an antiviral AIDS medication that was being developed by the U.S. pharmaceutical company Gilead Sciences. Among other complaints, French-speaking trial subjects were given questionnaires written in English. Critics say the company was using Cameroonians as guinea pigs for profit-making.

    Reasons for Testing

    Until about 1995, most clinical trials were conducted in Europe, the United States and Japan. Today experts estimate that more than 100,000 trials are conducted in different countries every year, with 10 percent of them in the developing world and one percent in Africa.

    There are several reasons why drug companies are relocating clinical trials.

    Some researchers note that to obtain valid and timely results from HIV trials, the companies must test people in areas with high rates of infection. They also say the genetic variability of HIV requires that candidate vaccines be tested in different areas of the world where different strains are present.

    Dr. Mona Khanna of  the University of Illinois College of Medicine, says for the drug companies, there’s also a large number of willing participants.

    "I think the reason so many clinical trials are being done in Africa is because they have a lot of people," said Khanna. That’s the first thing. So you can find many men, women and children, whatever you need, very quickly. They also have low cost. In other words, for companies to conduct trials in the US there’s a lot of cost associated with it, whereas in Africa, you go and set up a clinic; it’s much less cost."

    Sonia Shah, author of the book Body Hunters, says many subjects are not aware of the procedure, or their rights, thus reducing the risk of expensive litigation.

    Critics say many subjects also do not understand the rules of the trials: literacy rates are low, written agreements are misunderstood and many come from cultures that accept authority without question. In some cases, subjects are pressured into the trials by local committees, some which may receive pay from the companies. They may also feel they can not quit a clinical trial because they or their children would lose out on good health care or treatment.

    Calls for change

    One of those advocating change is Professor Ames Dhai, director of the Steve Biko Center for Bioethics in Johannesburg and a lecturer at Witswatersrand University. She says Africa must stop blaming the West and assume responsibility for monitoring the trials.

    "I think we need to blame ourselves if nothing is changing," said Dhai, "and I think it’s time we stopped blaming the West and started looking at ourselves and how we can approach the issue. We all spend a lot of time looking at informed consent, regulatory and administrative issues. But we don’t spend enough time looking at justice in terms of what’s going to happen after the trials – have our populations been exploited in the process of research?"

    Dhai mentions poor governance, corruption, conflicts, illiteracy and lack of knowledge about drugs as factors contributing to the inability of many African countries to review the proposals and monitor the trials.

    Dr.  Mona Khanna of the University of Illinois says African countries must set up effective ethics committees and establish sanctions.

    "If there are no penalties associated with enforcement," she said, "people will do whatever they want to do. If the local authorities or regulatory bodies find companies that are doing ABC or D, you have to fine them or tell them [they] can never come back."

    Author Sonya Shah says African leaders should introduce legislation requiring drug trial funders to contribute to local scientific research with medical equipment and programs that would benefit communities.

    Others say because the US Food and Drug Administration lacks the resources to monitor overseas trials, countries should form their own ethics committees to ensure drug testing benefits the communities involved.

    They also say some procedures could be changed.

    Today, many test a new drug against a placebo, a treatment known to be ineffective. That’s cheaper for the companies, but patients taking placebos are not receiving any treatment. Critics say a better idea would be to replace a placebo – when possible -- with an older or less effective drug. At least that way, they say all of the subjects will get some type of treatment that may benefit them.

    But even critics like Professor Khanna agree that the trials, when scrutinized more effectively, can help advance the fight against HIV, malaria and other diseases on the continent.

    Today Africa is one of the biggest beneficiaries of free and discounted medicines from the West. The Global Fund for the Fight against HIV/AIDS, Malaria and TB, and the U.S.-backed President’s Emergency Plan for AIDS Relief (PEPFAR) are among several programs working to ensure that Africans get medication at affordable rates.

    You May Like

    Syrian Torture Victim Recounts Horrors

    'You make them think you have surrendered' says Jalal Nofal, a doctor who was jailed and survived repeated interrogations in Syria

    Mandela’s Millions Paid to Heirs, But Who Gets His Country Home?

    Saga around $3 million estate of country's first democratic president is far from over as Winnie Mandela’s fight for home overshadows payouts

    Guess Which Beach is 'Best in the US'?

    Hawaii’s Hanauma Bay tops an annual "top 10" list compiled by a coastal scientist, also known as Doctor Beach

    This forum has been closed.
    Comments
         
    There are no comments in this forum. Be first and add one

    By the Numbers

    Featured Videos

    Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
    Chinese-Americans Heart Trump, Bucking National Trendi
    X
    May 27, 2016 5:57 AM
    A new study conducted by three Asian-American organizations shows there are three times as many Democrats as there are Republicans among Asian-American voters, and they favor Hillary Clinton over Donald Trump. But one group, called Chinese-Americans For Trump, is going against the tide and strongly supports the business tycoon. VOA’s Elizabeth Lee caught up with them at a Trump rally and reports from Anaheim, California.
    Video

    Video Chinese-Americans Heart Trump, Bucking National Trend

    A new study conducted by three Asian-American organizations shows there are three times as many Democrats as there are Republicans among Asian-American voters, and they favor Hillary Clinton over Donald Trump. But one group, called Chinese-Americans For Trump, is going against the tide and strongly supports the business tycoon. VOA’s Elizabeth Lee caught up with them at a Trump rally and reports from Anaheim, California.
    Video

    Video Reactions to Trump's Success Polarized Abroad

    What seemed impossible less than a year ago is now almost a certainty. New York real estate mogul Donald Trump has won the number of delegates needed to secure the Republican presidential nomination. The prospect has sparked as much controversy abroad as it has in the United States. Zlatica Hoke has more.
    Video

    Video Drawings by Children in Hiroshima Show Hope and Peace

    On Friday, President Barack Obama will visit Hiroshima, Japan, the first American president to do so while in office. In August 1945, the United States dropped an atomic bomb on the city to force Japan's surrender in World War II. Although their city lay in ruins, some Hiroshima schoolchildren drew pictures of hope and peace. The former students and their drawings are now part of a documentary called “Pictures from a Hiroshima Schoolyard.” VOA's Deborah Block has the story.
    Video

    Video Vietnamese Rapper Performs for Obama

    A prominent young Vietnamese artist told President Obama said she faced roadblocks as a woman rapper, and asked the president about government support for the arts. He asked her to rap, and he even offered to provide a base beat for her. Watch what happened.
    Video

    Video Roots Run Deep for Tunisia's Dwindling Jewish Community

    This week, hundreds of Jewish pilgrims are defying terrorist threats to celebrate an ancient religious festival on the Tunisian island of Djerba. The festivities cast a spotlight on North Africa's once-vibrant Jewish population that has all but died out in recent decades. Despite rising threats of militant Islam and the country's battered economy, one of the Arab world's last Jewish communities is staying put and nurturing a new generation. VOA’s Lisa Bryant reports.
    Video

    Video Meet Your New Co-Worker: The Robot

    Increasing numbers of robots are joining the workforce, as companies scale back and more processes become automated. The latest robots are flexible and collaborative, built to work alongside humans as opposed to replacing them. VOA’s Tina Trinh looks at the next generation of automated employees helping out their human colleagues.
    Video

    Video Wheelchair Technology in Tune With Times

    Technologies for the disabled, including wheelchair technology, are advancing just as quickly as everything else in the digital age. Two new advances in wheelchairs offer improved control and a more comfortable fit. VOA's George Putic reports.
    Video

    Video Baby Boxes Offer Safe Haven for Unwanted Children

    No one knows exactly how many babies are abandoned worldwide each year. The statistic is a difficult one to determine because it is illegal in most places. Therefore unwanted babies are often hidden and left to die. But as Erika Celeste reports from Woodburn, Indiana, a new program hopes to make surrendering infants safer for everyone.
    Video

    Video California Celebration Showcases Local Wines, Balloons

    Communities in the U.S. often hold festivals to show what makes them special. In California, for example, farmers near Fresno celebrate their figs and those around Gilmore showcase their garlic. Mike O'Sullivan reports that the wine-producing region of Temecula offers local vintages in an annual festival where rides on hot-air balloons add to the excitement.
    Video

    Video US Elementary School Offers Living Science Lessons

    Zero is not a good score on a test at school. But Discovery Elementary is proud of its “net zero” rating. Net zero describes a building in which the amount of energy provided by on-site renewable sources equals the amount of energy the building uses. As Faiza Elmasry tells us, the innovative features in the building turn the school into a teaching tool, where kids can't help but learn about science and sustainability. Faith Lapidus narrates.

    Special Report

    Adrift The Invisible African Diaspora